Lords Mark Industries entered a strategic collaboration with ARKALL Holdings Limited on August 24, 2026, to expand its healthcare footprint across the Caribbean region. The partnership focuses on establishing pathology laboratories and commercializing medical devices, diagnostics, and equipment.

The agreement marks the company’s entry into the Caribbean market through a phased expansion model. Initial operations will commence in Trinidad & Tobago, with progressive extension to other markets over the next three years. Lords Mark will supply IVD products, rapid test kits, biochemistry reagents, dialysis machines, and technical support, while ARKALL leads commercialization and market development.

Financial Projections

Based on internal management assessments, the phased rollout has the potential to generate approximately US$100 million in export revenue between FY27 and FY31. This projection is subject to successful implementation, regulatory approvals, and market penetration. The company estimates the indicative pathology and diagnostics opportunity across the identified Caribbean markets at approximately US$1.24 billion.

These figures represent forward-looking statements. Actual results may vary materially depending on business conditions, regulatory factors, and execution pace.

Deal Structure

ARKALL Holdings Limited will undertake 100% of the investments required for the Caribbean expansion, including scaling laboratory operations. Lords Mark provides product supply, training, and operational guidance without capital outlay for this specific venture.

Dr. Sachidanand Upadhyay, Managing Director & CEO of Lords Mark Industries, stated that the collaboration combines the company’s medical technology capabilities with ARKALL’s regional commercial presence. He described the partnership as a long-term platform for expanding export footprints while contributing to accessible healthcare infrastructure.

What the Numbers Show

The deal structure isolates capital expenditure risk for Lords Mark Industries. By securing a partner willing to fund 100% of the expansion costs while targeting US$100 million in revenue over five years, the company positions itself for high-margin export growth without immediate balance sheet impact. The disparity between the US$100 million revenue projection and the US$1.24 billion total market opportunity suggests significant room for share acquisition, contingent on execution speed against competitors.

Lords Mark Industries Limited delivered a strong start to FY27, reporting standalone revenue of ₹280 crore and a net profit of ₹32 crore for the quarter ended June 30, 2026. The diversified conglomerate highlighted a strategic shift toward higher-margin healthcare businesses, which now constitute the majority of its revenue stream.

Financial Performance

The company’s consolidated revenue for the quarter stood at ₹307 crore. Management provided a conservative revenue guidance of ₹1,550 crore for the full fiscal year, projecting year-on-year growth of approximately 20%. This guidance accounts for the seasonal nature of its business segments, particularly the government-funded projects that typically see higher execution in the second half of the financial year.

Segmental Breakdown

The revenue mix has tilted significantly toward the IVD and Medtech verticals. For Q1FY27, the healthcare segment contributed 55% of the total revenue, while the remaining 45% came from the renewable energy business. This structural change is driving margin expansion, as the healthcare division operates at an EBITDA margin of roughly 20%, compared to 11% in the renewable energy space.

What the Numbers Show

The divergence in operating margins between the two core businesses underscores the impact of product diversification on profitability. With healthcare generating nearly double the EBITDA margin of renewables, the growing contribution from the IVD and Medtech segment acts as a lever for overall margin improvement. As management targets healthcare to contribute at least 30% of total revenue through new product launches, the weighted average margin profile is poised to expand further.

Operational Updates

Management outlined several key operational developments:

• Dialysis Machines: The company has launched India’s first AI-based dialysis machine, manufactured by OEM partners including Bharat Electronics Limited (BEL). The average selling price is approximately ₹7.5 lakh, against a manufacturing cost of ₹4.5 lakh. An order book of over 500 machines exists across domestic and export markets.
• Renewable Energy Order Book: The LED and renewable energy division holds a running order book valued at around ₹3,000 crore.
• New Technologies: Technologies acquired from government institutions, including sickle cell testing from IIT Bombay and oral cancer diagnostics from Bhabha Atomic Research Centre, are in the approval stage with commercial launches expected by Q4FY27 or early FY28.

Capital Structure and Governance

Promoters currently hold an 80% stake in the company. To comply with SEBI listing norms requiring a minimum public holding, the board is evaluating options such as an Offer for Sale (OFS) or a rights issue. Management emphasized that the primary objective is to infuse capital into the business rather than facilitate promoter exit.

Regarding recent administrative changes, management clarified that the resignations of the Company Secretary and secretarial auditor were procedural outcomes of the reverse merger with Kratos Energy & Infrastructure Limited, necessitating the appointment of new compliance personnel.

Outlook

Looking ahead to FY28, management expects revenue growth to exceed the conservative 20% benchmark set for FY27. The launch of monopolistic technologies in oncology and hematology, alongside the scaling of dialysis centers, is projected to drive this acceleration. The company also plans to establish 50 dialysis centers across India during the current fiscal year.